Crinetics Pharmaceuticals

At Crinetics, diversity isn’t just a principle— it’s essential to our innovation and growth. This Global Diversity Awareness Month, we proudly celebrate the unique backgrounds, perspectives and experiences that enhance our team and drive our mission forward. By embracing inclusion, we unlock new ideas and foster a culture of innovation. Together, we are committed to transforming the future of endocrine care. #GlobalDiversityAwareness

Adrenocorticotropic hormone (ACTH) plays a crucial role in regulating cortisol, a vital hormone for our body's response to stress, metabolism, and immune function. For individuals living with classic congenital adrenal hyperplasia (CAH), ACTH levels are elevated relative to non-CAH individuals, increasing the risk of significant health consequences. There is a critical unmet need for treatments that can directly inhibit ACTH at its receptor for the effective management of CAH. Learn how we’re seeking to address the unmet needs of the CAH community: https://bit.ly/4dckgYd

At Crinetics, we believe mental health is fundamental to overall well-being. Living with chronic endocrine conditions can deeply impact mental health. The ongoing challenges of managing symptoms, treatments, and the uncertainty of the future add immense emotional strain to patients' daily lives. Today, on #WorldMentalHealthDay, we join the global community in highlighting the critical importance of mental wellness.

We are excited to join the World Alliance of Pituitary Organizations (WAPO) for the 2024 WAPO Global Summit! At Crinetics, we believe collaboration is essential to addressing the unmet needs of patients living with pituitary and endocrine-related disorders. The WAPO Global Summit is a crucial platform that unites patient advocacy leaders, healthcare professionals, and industry partners to share the latest medical breakthroughs and insights in pituitary disease care. Learn how we partner with patient organizations like WAPO to improve care for individuals living with pituitary-related conditions: crinetics.com/patients.

We’re thrilled to announce that our Crinetics HR was named a top finalist for the San Diego HR Executive Team award! This honor recognizes HR teams that make a powerful impact across industries while championing teamwork within their organizations and the broader San Diego HR community. A huge congratulations to our dedicated team for their commitment to nurturing talent and driving transformation!

Join us in supporting the CARES Foundation, Inc on Tuesday, October 1, 2024, at 10:00 AM (ET) for a virtual Externally Led Patient-Focused Drug Development Meeting. This meeting with the FDA is an opportunity for patients, families, caregivers, and advocates to voice their experiences with symptoms, daily challenges, and current treatments. Your valuable insights can directly shape the FDA’s decisions during drug development and the review of new treatments. Register here to be part of this important conversation: https://bit.ly/3TOn2vq

We are excited to announce the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for the first oral, once-daily, selectively-targeted somatostatin receptor type 2 agonist in development for the treatment of acromegaly. This marks the first NDA submission for Crinetics as a company, and we are grateful to all who made this milestone possible! We are now one step further along in our mission to transform the lives of people living with a wide range of endocrine-related diseases. Learn more: https://bit.ly/3XIQ5Sb

We were honored to attend the CARES Foundation, Inc Education Conference and Patient Advisory Summit, supporting our mutual commitment to advancing care for the #CAH community. As we advance our clinical trial program in CAH, we are committed to partnering with leading patient organizations like CARES to address unmet needs and make a meaningful difference in the lives of individuals living with this condition.

For some patients undergoing treatment for acromegaly, gastrointestinal (GI) side effects may not be addressed. These side effects can interfere with daily life and significantly impact a patient’s overall well-being. Hear from #acromegaly patients about the GI side effects they experience during their treatment cycle: https://lnkd.in/d2aribMF

The current standard of care for treating #acromegaly can create an emotional impact for patients. It is important to recognize this impact and to account for the emotional needs of patients. Learn more about the emotional impact of acromegaly treatment on patients: https://lnkd.in/g4jBe9HW